Close Menu

multiplex PCR

The assay should have a CE-IVD mark by November and will serve the Finnish molecular diagnostics firm's growing European client base.

Both RT-PCR tests are for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B from throat swab samples.

The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.

The 45-minute test was developed by BioMérieux subsidiary BioFire Defense and can be used on the company's FilmArray and FilmArray Torch systems.

Technology partners on the study include BioMérieux and SkylineDx, as well as Imperial College London's biomedical electronics unit.

LGC will be Swift's worldwide partner for amplicon-based targeted sequencing assays for genotyping AgBio samples, including crop species and animals. 

The company announced the launch of the new products in the US and Europe as part of a product portfolio it has named Panther Scalable Solutions.

Perceptive Advisors led the round, joined by new and existing investors. ArcherDx will use the proceeds to launch a companion diagnostic and expand globally.

The firm will use the new funds to accelerate development of products, expand partnerships, and support commercialization of its two multiplex panels.

The firm has entered the market in Africa with a new collaboration in Ghana. It is also developing instrument-agnostic STI and liquid biopsy tests.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.